article thumbnail

Fulgent Genetics Extends Partnership with New York City Test and Trace for COVID-19 Testing, Awarded Contract for 2021 School Year

The Pharma Data

The Corps is a group of doctors, public health professionals and community advocates working to reverse the COVID-19 outbreak and protect our city. Through its robust and citywide partnerships, The Corps helps New Yorkers receive free, safe and confidential testing for COVID-19 and for the antibody test. About Fulgent Genetics.

article thumbnail

A Horizon of hope: UPLIZNA data, NMOSD, and ECTRIMS

pharmaphorum

Depending on a patient’s underlying genetic makeup, it can affect anywhere between 0.4 Yet, according to NMO UK , others might also have antibodies recognised as being associated with this disorder, such as Aquaporin 4 (AQP4) and Myelin Oligodendrocyte Glycoprotein (MOG). to two or three people out of 100,000. Patterson explained.

Antibody 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Advancements in upstream CLD for enhanced biotherapeutics production

Drug Discovery World

As the significance of large molecules continues to broaden across diverse modalities, emphasis on bispecific and multispecific antibodies to treat various disorders such as rheumatologic diseases, cancer, diabetes, anaemia, and infectious diseases becomes paramount. References Mistry RK, Kelsall E, Sou SN, et al.

article thumbnail

Roctavian Becomes First Gene Therapy for Severe Hemophilia A to Get FDA Nod

XTalks

Hemophilia A is a rare genetic bleeding disorder that is caused by a mutation in the gene that encodes the key blood clotting protein factor VIII (FVIII). Severe hemophilia A is usually treated with FVIII replacement therapy or an antibody-based drug to improve the ability of blood to clot and reduce the likelihood of bleeding.

article thumbnail

Moderna and BioNTech – who are they?

pharmaphorum

As it’s just a messenger molecule, it does not affect the body’s own genetic code when it is injected as a vaccine – but what it does do is instruct cells to code for copies of a certain protein. The body produces antibodies against the protein, which neutralise the virus in the event of an infection.

article thumbnail

Advances in Rare Disease Drug Development: Disease Biology, Regulatory Support, Building Relationships and the Patient Voice

XTalks

IgA nephropathy is much more common in China, with estimates of 5 million people with the condition, which could be linked to differences in genetic makeup and environmental factors. However, in IgA nephropathy, this pathogenic IgA enters the systemic circulation and due to certain properties of the antibody, elicits an autoimmune response.

article thumbnail

What Do Patients Have to Say about Gene Therapy Trials? An Upcoming FDA Public Meeting to Hear from Patients and Caregivers

FDA Law Blog

In 1999, Jesse Gelsinger, age 18, died four days after doctors at the University of Pennsylvania administered a corrective gene encased in a deactivated adenovirus. We were able to phase out the antibody infusions he was getting, and, best of all, we were allowed to start interacting with the world! No more living in isolation!